Correlation Between Vincerx Pharma and Editas Medicine
Can any of the company-specific risk be diversified away by investing in both Vincerx Pharma and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vincerx Pharma and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vincerx Pharma and Editas Medicine, you can compare the effects of market volatilities on Vincerx Pharma and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vincerx Pharma with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vincerx Pharma and Editas Medicine.
Diversification Opportunities for Vincerx Pharma and Editas Medicine
0.9 | Correlation Coefficient |
Almost no diversification
The 3 months correlation between Vincerx and Editas is 0.9. Overlapping area represents the amount of risk that can be diversified away by holding Vincerx Pharma and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and Vincerx Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vincerx Pharma are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of Vincerx Pharma i.e., Vincerx Pharma and Editas Medicine go up and down completely randomly.
Pair Corralation between Vincerx Pharma and Editas Medicine
Given the investment horizon of 90 days Vincerx Pharma is expected to under-perform the Editas Medicine. In addition to that, Vincerx Pharma is 4.32 times more volatile than Editas Medicine. It trades about -0.02 of its total potential returns per unit of risk. Editas Medicine is currently generating about -0.09 per unit of volatility. If you would invest 134.00 in Editas Medicine on October 20, 2024 and sell it today you would lose (12.00) from holding Editas Medicine or give up 8.96% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Vincerx Pharma vs. Editas Medicine
Performance |
| Timeline |
| Vincerx Pharma |
| Editas Medicine |
Vincerx Pharma and Editas Medicine Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Vincerx Pharma and Editas Medicine
The main advantage of trading using opposite Vincerx Pharma and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vincerx Pharma position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.| Vincerx Pharma vs. Spero Therapeutics | Vincerx Pharma vs. Bolt Biotherapeutics | Vincerx Pharma vs. Coherus BioSciences | Vincerx Pharma vs. Applied Therapeutics |
| Editas Medicine vs. Beam Therapeutics | Editas Medicine vs. Crispr Therapeutics AG | Editas Medicine vs. Caribou Biosciences | Editas Medicine vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |